Same Struggles, Different Reasons: Patients and Caregivers Walk Parallel Paths in Multiple Myeloma

Multiple myeloma has quietly become one of oncology’s most striking success stories of the past two decades. A cancer of plasma cells inside the bone marrow, it once carried a prognosis measured in months; today, thanks to proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation, many patients live for years, sometimes decades, with a disease that is treated as chronic even though it remains incurable. But that clinical triumph has created a new and less visible problem. People are living longer with relapsing, remitting cancer, and the burden of that long journey does not fall on patients alone. A new mixed-methods study from a university-affiliated cancer center in Seoul, published in BMC Cancer, offers one of the most detailed paired portraits yet of how patients with multiple myeloma and their family caregivers experience the same disease from opposite sides of the hospital bed, and the findings reveal a paradox that could reshape how supportive care is delivered.

The research team, led by investigators at Sungkyunkwan University School of Medicine and Samsung Medical Center, recruited 44 patient-caregiver dyads, a total of 88 participants, between October 2021 and March 2022. Every participant completed both a quantitative survey and a separate, semi-structured in-depth interview, with patients and their caregivers interviewed individually rather than together. This dyadic design is methodologically important. Much of the existing literature on cancer caregiving relies on either patient reports or caregiver reports, which risks missing the interpersonal dynamics within a household. By interviewing both members of each pair and analyzing their accounts side by side, the researchers could compare not just what challenges each person faced, but why they faced them, and whether the two members of a dyad understood each other’s struggles. The final analytic sample included 41 patients and 38 caregivers, of whom 21 were spouses and 17 were adult children, reflecting the typical structure of family caregiving in Korea.

The quantitative backbone of the study came from two well-validated instruments. Psychological distress was measured with the Distress Thermometer, a simple self-report tool on which respondents rate their distress from 0 to 10, with scores of 4 or higher generally indicating clinically significant distress that warrants psychosocial intervention. Quality of life was assessed with the WHOQOL-Brief, the World Health Organization’s abbreviated instrument covering physical, psychological, social, and environmental domains. The results showed that patients and their spousal caregivers reported strikingly similar levels of distress, with mean Distress Thermometer scores of 4.2 for patients and 3.9 for spouses, both accompanied by wide standard deviations of 2.5 and 2.8 respectively, indicating substantial variability across individuals. Both groups hovered around the conventional threshold for significant distress, a signal that the emotional toll of multiple myeloma is shared almost symmetrically within couples.

The qualitative interviews, however, revealed that this numerical similarity conceals a profound asymmetry. Patients described a cascade of challenges flowing directly from the disease itself: reduced physical function, diminished psychological resilience, weakened spiritual well-being, and strained relationships with family and friends. Because multiple myeloma relapses and recurs, patients live in a cycle of treatment, remission, and relapse, never reaching the stable survivorship that patients with some other cancers may achieve. Bone pain, fatigue, anemia, and infection risk, all hallmarks of plasma cell malignancy, erode the ability to work, exercise, and maintain social roles. Each relapse forces patients to confront mortality again, restart treatment, and renegotiate their expectations for the future. The interviews captured how this uncertainty seeps into daily life, making long-term planning feel precarious and turning routine follow-up appointments into moments of renewed anxiety.

Caregivers reported facing almost exactly the same list of challenges: physical exhaustion, psychological strain, spiritual questioning, and social isolation. But when the researchers probed the underlying reasons, the picture diverged sharply. For caregivers, the dominant driver was not the cancer itself but the burden of caring for the patient and managing the needs of the wider family. Spouses, in particular, described absorbing the logistics of treatment schedules, medication management, transportation to the hospital, dietary adjustments, and the emotional labor of staying optimistic while privately fearing the next relapse. Adult children, who in the Korean context often balance caregiving with employment and their own young families, described the competing demands of filial duty and modern working life. Financial stress emerged as a distinctly caregiver-centered concern, encompassing both direct treatment costs and the indirect losses that follow when a patient can no longer work and a family member reduces paid hours to provide care.

This divergence, similar symptoms with different roots, is the study’s central and most consequential finding. It means that a household affected by multiple myeloma can appear, from the outside, to be coping coherently, while the two people inside it are suffering for reasons the other may not fully grasp. A patient’s irritability may stem from bone pain and steroid side effects; a caregiver’s withdrawal may stem from exhaustion and financial worry. Without explicit communication, each can misread the other’s distress as lack of understanding or lack of effort, compounding the strain on the relationship precisely when the relationship is the main source of support. The authors argue that this mutual misunderstanding is itself a modifiable target for intervention, one that current clinical practice rarely addresses because supportive care is typically organized around the patient, with caregivers assessed, if at all, as an afterthought.

The clinical implications are significant. As survival in multiple myeloma continues to extend, the cumulative demand on family caregivers grows in parallel, and the study suggests that caregiver distress is not a secondary phenomenon that resolves when the patient stabilizes; it tracks the patient’s distress closely and persists across the relapsing course of the disease. Supportive care programs that treat the patient and caregiver as a dyad, rather than as separate and unequal participants, could screen both members for distress at each clinical milestone, offer psychoeducation tailored to each role, and facilitate structured communication between them. For patients, interventions might focus on symptom management, uncertainty, and meaning-making; for caregivers, on respite care, financial counseling, and practical caregiving skills. The study’s authors conclude that tailored support systems fostering mutual understanding are essential for improving overall well-being throughout the myeloma journey, a formulation that moves beyond the generic call for more psychosocial services toward a specific, testable model of dyadic care.

The study also carries broader lessons for oncology as a whole. Multiple myeloma is an early example of a wider transformation: as novel therapeutics convert once-fatal malignancies into long-term chronic conditions across many cancer types, the supportive care needs of patients and families will increasingly define the quality of cancer care. Survivorship research has historically centered on the patient, and caregiver science has often been siloed within gerontology or palliative care. Dyadic designs like this one, pairing patients and caregivers within the same study and comparing their accounts directly, offer a template for understanding how illness is experienced as a shared but asymmetric enterprise. The Seoul team’s work was approved by the Samsung Medical Center Institutional Review Board and conducted in accordance with the Declaration of Helsinki, with informed consent from all participants, and it was supported by a grant from Janssen Korea, with the authors reporting no competing interests.

What lingers after reading the study is the image suggested by its title: two people traveling parallel journeys through the same landscape, encountering the same obstacles, for entirely different reasons. Modern hematology has become remarkably good at extending the length of that journey. The challenge now, this research makes clear, is to make sure that both travelers are seen, understood, and supported along the way, not only the one with the diagnosis. For the millions of households worldwide living with multiple myeloma, and for the growing number living with other cancers transformed into chronic diseases, that shift in perspective, from treating a patient to caring for a relationship, may prove as important as any drug in the pipeline.

Subject of Research: Life challenges and supportive care needs of multiple myeloma patients and their family caregivers

Article Title: Parallel journeys, similar challenges, and different reasons: navigating life challenges in multiple myeloma from the perspectives of patients and caregivers

Article References: Kim, S., Park, Y., Kim, N., Park, J., Bang, G., Kim, K., Yoon, S. E., Kang, D., Kim, S. J., & Cho, J. (2026). Parallel journeys, similar challenges, and different reasons: navigating life challenges in multiple myeloma from the perspectives of patients and caregivers. BMC Cancer. https://doi.org/10.1186/s12885-026-17045-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17045-4

Keywords: multiple myeloma, caregivers, quality of life, psychological distress, dyadic study, supportive care, survivorship, caregiving burden, oncology, qualitative research, family caregiving, BMC Cancer